drugset / Trial / NCT03731221

Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine

NCT03731221

Phase 0 Completed 196 enrolled The Cleveland Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-based randomization. Assignments will be based on computer-generated code. Clinicians will not be blinded to the intervention, but all outcomes will be assessed by research personnel who are blinded to the group assignment.

Timeline

Start
2018-11-01
Primary completion
2024-09-19
Completion
2024-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 2.5 mg/kg Other
Subject Bupivacaine Other / unclassified 150 mg Other
Subject Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.